Featured Press Releases

New FDA-Cleared Treatment for Fibromyalgia Symptoms from Swing Therapeutics Covered by Highmark

New FDA-Cleared Treatment for Fibromyalgia Symptoms from Swing Therapeutics Covered by Highmark

Medit introduces SmartX, a new All-on-X solution for digital dentistry

Medit introduces SmartX, a new All-on-X solution for digital dentistry

  • 18 Mar 2025

Medit a global leader in digital dentistry, has launched its latest All-on-X solution, Medit...

Exicure, Inc. (Nasdaq: XCUR) Unveils Next Steps Toward New Clinical Trial in Acute Myeloid Leukemia (AML)

Exicure, Inc. (Nasdaq: XCUR) Unveils Next Steps Toward New Clinical Trial in Acute Myeloid Leukemia (AML)

GoodRx has announced a collaboration with Novo Nordisk to offer expanded access to Ozempic® and Wegovy® for $499 per month

GoodRx has announced a collaboration with Novo Nordisk to offer expanded access to Ozempic® and Wegovy® for $499 per month

Mexico’s First Pharmaceutical Company, IFA Celtics, Deploys ForgeStop

Mexico’s First Pharmaceutical Company, IFA Celtics, Deploys ForgeStop's NFC Anti-Counterfeit Tech

AVANTIK Appoints Jeffrey Waldman as Chief Executive Officer

AVANTIK Appoints Jeffrey Waldman as Chief Executive Officer

Tenpoint Therapeutics Announces the Launch of the YUVEZZI™ Telehealth Prescribing Program

Tenpoint Therapeutics Announces the Launch of the YUVEZZI™ Telehealth Prescribing Program

  • Tenpoint Therapeutics, Ltd.
  • 09 Nov 2026
BE BOLD: BIMZELX® (bimekizumab-bkzx) demonstrates superior joint response rates versus SKYRIZI® (risankizumab-rzaa) at Week 16, with sustained clinical improvements through Week 24

BE BOLD: BIMZELX® (bimekizumab-bkzx) demonstrates superior joint response rates versus SKYRIZI® (risankizumab-rzaa) at Week 16, with sustained clinical improvements through Week 24

  • UCB
  • 09 Nov 2026
Johnson & Johnson announces that ICOTYDE® (icotrokinra), a once-daily targeted oral peptide, delivers significant improvements in psoriatic arthritis disease activity among biologic-naïve patients

Johnson & Johnson announces that ICOTYDE® (icotrokinra), a once-daily targeted oral peptide, delivers significant improvements in psoriatic arthritis disease activity among biologic-naïve patients

  • Johnson & Johnson
  • 08 Nov 2026
Lilly and Hims & Hers expand access to Lilly

Lilly and Hims & Hers expand access to Lilly's FDA-approved medicines

  • Hims & Hers
  • 06 Nov 2026
Roche Receives FDA 510(k) Clearance for New cobas® eplex Respiratory Pathogen Panel 3, Enabling Customized Respiratory Testing to Meet Local Patient Needs

Roche Receives FDA 510(k) Clearance for New cobas® eplex Respiratory Pathogen Panel 3, Enabling Customized Respiratory Testing to Meet Local Patient Needs

  • Roche Diagnostics
  • 02 Nov 2026
Superpower Launches Peptide Services, Connecting Comprehensive Blood Testing With Prescription Peptide Care

Superpower Launches Peptide Services, Connecting Comprehensive Blood Testing With Prescription Peptide Care

  • Superpower
  • 02 Nov 2026

Most Popular
November   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30            

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.